BAFNAPHNSEBafna Pharmaceuticals LimitedMediumNeutral
Announced Tue, 12 Aug · 18:01 IST

Bafna Pharmaceuticals Limited has informed the Exchange regarding Change in Director(s) of the company.

Management Changes View source PDF

BAFNAPH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Bafna Pharmaceuticals announced board changes on August 12, 2025. Mrs. Ravichandran Chitra has been re-appointed as a Non-Executive Independent Director for a second term of 5 years, effective November 12, 2025. Mr. Palamadai Krishnan Sundaresan has also been re-appointed as a Non-Executive Independent Director for a second term of 5 years, effective September 19, 2025. Mr. Bafna Mahaveer Chand has been re-appointed as Chief Executive Officer for a further term of 5 years, effective September 10, 2025. Both independent director re-appointments are subject to shareholder approval at the upcoming Annual General Meeting.

Likely market impact

These are routine re-appointments indicating leadership continuity. Shareholders should expect stability in governance and management direction. No material impact on stock price is anticipated as there are no new faces or resignations involved.